CGEM Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 19.08%, SMA50 31.65%, SMA200 70.92%). The stock’s 14-day RSI is 73.06 (overbought), while the ATR of 0.92 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 4.46% below its high and over 167.78% above its low. Average 10-day trading volume of 1.07 million shares is slightly above the 3-month average of 887.18 thousand, indicating heightened recent market interest.

Cullinan Therapeutics, Inc. has 59.07 million shares outstanding. The public float is 36.05 million shares, elevated short interest at 12.23% of float. This equals 6.24 million shares. The short ratio is 16.28 days. Institutional investors hold 112.71% of the float. Insiders own 4.54%. Lynx1 Capital Management LP holds 8.96 million shares, UBS Oncology Impact Fund L.P. has 7.65 million shares and LAMPERT MARK N has 4.06 million shares. Over the past six months, insider transactions show net selling. They sold 104.37 thousand shares across 22 transactions.

Cullinan Therapeutics, Inc. generated EPS of -$3.68 over the past year. Five-year average earnings growth is -45.66%. Wall Street analysts project EPS growth of -1.6% annually over the next five years. The latest quarter delivered EPS of -$0.75. The next quarter is forecast at -$0.81. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $38.00 to $24.00. The high target offers 181.27% upside. The low target suggests 77.65% downside. The mean target is $32.06. This offers 137.31% upside. Cullinan Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by -10.27%. The prior quarter beat by -3.75%. Over the last six quarters, Apple has recorded several small beats. These include -2.67% in February 27, 2025.

Cullinan Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading above this model’s fair value.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) closed at $13.51 USD, losing -$0.92 (-6.38%) from the previous close of $14.43. The stock is currently mid-range between its 52-week high and low $5.68 and $16.74. With a market capitalization of about $830.30 million, Cullinan Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.09). Key stats such as the average daily volume over the past year has been around 884.30 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Cullinan Therapeutics, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Nadim Ahmed, the company employs approximately 111 people and listed since January 08, 2021. Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies.

Cullinan Therapeutics, Inc. trades at a P/E ratio of -3.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.21 suggesting the stock is closer to book value. The P/FCF stands at -4.7, also above market averages.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) shares are flat 5.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cullinan Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.66. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $35.60, suggesting 163.51% upside. Our AI forecast model points to short-term strength (8.29% over two weeks), a medium-term fall (-51.74% over three months), and a longer-term gain (188.45% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cullinan Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.29%, with price expected at $14.63 by June 19, 2026, within a range of $13.64 to $15.75 3-Month Outlook: Projected fall of -51.74%, reaching $6.52 by September 03, 2026, with a range of $6.11 to $6.96. 1-Year Outlook: Projected gain of 188.45%, with price at $38.97 by June 04, 2027, within a range of $36.06 to $48.53.